IPOs for 2013: Prosensa

IPO Prosensa Holding (RNA) is a biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Their primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. Prosensa's clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy, or DMD.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus

IPOs for 2013: Tremor Video

IPO Tremor Video (TRMR) is a provider of video advertising solutions for internet-connected devices including computers, smartphones, tablets and connected TVs. Their proprietary technology, VideoHub, optimizez video ad campaigns for brand-centric metrics and provides advertisers with analytics and measurement tools enabling them to understand why, when and where viewers engage with their video ads. Tremor specializes in in-stream video advertisements, which are served to viewers immediately prior to or during the publisher's content, in contrast to traditional in-banner video advertising which is served on the periphery of publisher content.

Get an advisory report for this company's Initial Public Offering
View this company's prospectus

IPOs for 2013: Luxoft Holding

IPO Luxoft Holding (LXFT) is a provider of software development services and IT solutions to a global client base consisting primarily of large multinational corporations. Their software development services consist of custom software development and support, product engineering and testing, and technology consulting. Their services and solutions enable clients to increase efficiency, shorten time-to-market, and enhance their end user experience. Luxoft focuses on six industry verticals that have significant and growing demand for IT services: financial services; travel and aviation; technology; telecom; automotive and transport; and energy.

Get an advisory report for this company's Initial Public Offering
View this company's prospectus

An article on Five Below

Scott Sweet, senior managing partner of IPO Boutique, was quoted in the The Street on Friday:

"Five Below was hit pretty hard yesterday as was most everything," Sweet said. "I often see on deals that IPOs and secondary [offerings] postponed due to market conditions. In this case it was probably legit."

The full article is available here: http://www.thestreet.com/print/story/11957671.html


Scott offers research packages for IPOs including Five Below at IPO Boutique.
The same research information is also available on a global scale at IPO Global Research.

An article on Coty

Scott Sweet, senior managing partner of IPO Boutique, was quoted in the The Fresno Bee on yesterday:

Scott Sweet, senior managing partner at IPOBoutique.com, said in a phone interview that Coty's first day of trading has been disappointing and surprising so far given the high level of brand awareness that the company has.

The full article is available here: http://www.fresnobee.com/2013/06/13/3341380/coty-falls-in-1st-day-of-trading.html

Scott offers research packages for IPOs including Coty at IPO Boutique.
The same research information is also available on a global scale at IPO Global Research.

IPOs 2013: PTC Therapeutics

IPO PTC Therapeutics (PTCT) is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Their lead product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. PTC Therapeutics applies proprietary technologies and knowledge of post-transcriptional control processes in drug discovery and development activities. They discovered ataluren by applying their technologies to identify molecules that promote or enhance the suppression of nonsense mutations.

Get an advisory report for this company's Initial Public Offering
View this company's prospectus

IPOs 2013: bluebird bio

IPO bluebird bio, Inc. (BLUE) is a clinical-stage biotechnology company focused on treating severe genetic and orphan diseases using gene therapy. Many diseases have a genetic aspect whereby a mutated gene linked to a disease is passed down from generation to generation. Gene therapy has the potential to correct the underlying genetic defect that is the cause of the disease, rather than offering solutions that only address the symptoms. Bluebird and their scientific collaborators have generated what they believe is human proof-of-concept data for their gene therapy platform in two underserved diseases, each of which has been granted orphan drug status by U.S. and European regulatory authorities.

Get an advisory report for this company's Initial Public Offering
View this company's prospectus